Overview

Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
- To evaluate non-inferiority in the efficacy of HMR1964 as compared with Insulin lispro in terms of the change in HbA1C from baseline to endpoint. - To compare the safety of HMR1964 with insulin lispro.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Insulin
Insulin glulisine
Insulin, Globin Zinc